Larimar Therapeutics, Inc. Common Stock
Here’s whether Larimar Therapeutics, Inc. Common Stock (LRMR) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: 50-day MA is rising (+5.46% over 10 days); strong 1-year return of +37.8%; 3-month momentum positive (+12.2%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); RSI 12 — oversold. Currently 38.6% off its 52-week high. Score: -1/7.
LRMR is trading below its 200-day MA ($4.00) — a key warning sign the longer-term trend is under pressure. An RSI of 11.7 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +37.8% compares to +27.9% for SPY (beat the market by 9.9%). The current 38.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.